Tradestie Institutional Equity Comparison Engine · Market Close Sep 23, 2026

XOMA vs TBPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: XOMA 2 – 3 TBPH (1 Tie) Matrix Metrics: XOMA 4 – 6 TBPH

As of Sep 23, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over XOMA Royalty Corporation (XOMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).

  • Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.9% vs. -3.9% operating margin) and revenue trajectory (-20.9% vs. -22.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs TBPH
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96

6-Pillar Scorecard Institutional Category Breakdown (XOMA 2 – 3 TBPH)

Columns: Metric · XOMA · TBPH
1. Valuation Multiples TBPH
Forward P/E 21.5x 13.4x
Trailing P/E 28.2x 16.4x
PEG Ratio N/M N/M
EV / Revenue 16.1x 8.5x
2. Growth & Scale TBPH
Revenue Growth (YoY) -22.6% -20.9%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $104M
Market Cap $781.8M $884.2M
3. Profitability & Quality XOMA
Gross Margin 99.0% 75.1%
Operating Margin -3.9% 8.9%
Net Profit Margin 69.6% 51.6%
Return on Equity (ROE) 34.2% 20.9%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA $11M EBITDA
Cash Flow Margin 17.1% EBITDA Mgn 10.6% EBITDA Mgn
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $5.58 Book/Sh · 20.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 101.5% (100th %ile) 55.0% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity N/A 66.2% of Rev ($69M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (4) vs TBPH (6)
Institutional Metric XOMA TBPH Criterion Row Edge
Market Capitalization
Scale
$781.8M $884.2M Larger Scale TBPH
Trailing P/E Ratio
Valuation
28.2x 16.4x Lower Multiple TBPH
Forward P/E Ratio
Valuation
21.5x 13.4x Lower Multiple TBPH
Revenue Growth (YoY)
Growth
-22.6% -20.9% Higher Growth TBPH
Operating Margin (TTM)
Profitability
-3.9% 8.9% Higher Margin TBPH
Net Profit Margin
Profitability
69.6% 51.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% 20.9% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 50% ($13–$21) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 0.48β · 2% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M $104M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% 75.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) $11M EBITDA ($5.58 Book/Sh · 20.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +7.05 pp
XOMA: -3.81% · TBPH: +3.24%
3M Horizon XOMA +5.98 pp
XOMA: +9.34% · TBPH: +3.36%
6M Horizon XOMA +45.41 pp
XOMA: +34.26% · TBPH: -11.15%
1Y Horizon TBPH +12.01 pp
XOMA: +8.1% · TBPH: +20.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs TBPH. Trailing 12-month operating profitability (XOMA -3.9% vs TBPH 8.9%) and valuation multiples (XOMA 21.5x vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs TBPH Key Questions & Quantitative Answers

As of Sep 23, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over XOMA Royalty Corporation (XOMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.9% vs. -3.9% operating margin) and revenue trajectory (-20.9% vs. -22.6% YoY).

TBPH leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.

TBPH screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus TBPH (20.9% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Sep 23, 2026. For educational research only; not investment advice.